FDA approves Taro's Imiquimod Cream ANDA

Taro Pharmaceutical Industries Ltd. ("Taro," or the "Company," Pink Sheets: TAROF) reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application (ANDA) for Imiquimod Cream, 5% ("imiquimod cream").

Taro's imiquimod cream is a prescription pharmaceutical product used for topical treatment of actinic keratosis and external genital warts and is bioequivalent to Aldara® Cream, 5% of Graceway Pharmaceuticals, LLC.

According to industry sources, imiquimod cream had annual sales of approximately $340 million in the U.S.


Taro Pharmaceutical Industries Ltd.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
MOFs could help improve the delivery of genetic cargo into target cells